Theravance Biopharma Inc - Asset Resilience Ratio
Theravance Biopharma Inc (0TB) has an Asset Resilience Ratio of 37.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Theravance Biopharma Inc (0TB) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Theravance Biopharma Inc's Asset Resilience Ratio has changed over time. See Theravance Biopharma Inc (0TB) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Theravance Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Theravance Biopharma Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €154.91 Million | 37.29% |
| Total Liquid Assets | €154.91 Million | 37.29% |
Asset Resilience Insights
- Very High Liquidity: Theravance Biopharma Inc maintains exceptional liquid asset reserves at 37.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Theravance Biopharma Inc Industry Peers by Asset Resilience Ratio
Compare Theravance Biopharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Theravance Biopharma Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Theravance Biopharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.27% | €50.55 Million ≈ $59.10 Million |
€354.16 Million ≈ $414.05 Million |
-2.19pp |
| 2023-12-31 | 16.46% | €62.88 Million ≈ $73.51 Million |
€382.00 Million ≈ $446.60 Million |
+11.64pp |
| 2022-12-31 | 4.83% | €29.31 Million ≈ $34.27 Million |
€607.40 Million ≈ $710.11 Million |
-17.45pp |
| 2021-12-31 | 22.28% | €83.51 Million ≈ $97.63 Million |
€374.82 Million ≈ $438.20 Million |
-22.81pp |
| 2020-12-31 | 45.08% | €211.47 Million ≈ $247.24 Million |
€469.06 Million ≈ $548.38 Million |
-9.40pp |
| 2019-12-31 | 54.49% | €222.77 Million ≈ $260.44 Million |
€408.83 Million ≈ $477.96 Million |
+31.77pp |
| 2018-12-31 | 22.71% | €127.25 Million ≈ $148.77 Million |
€560.24 Million ≈ $654.97 Million |
-36.10pp |
| 2017-12-31 | 58.81% | €259.59 Million ≈ $303.48 Million |
€441.40 Million ≈ $516.04 Million |
+34.35pp |
| 2016-12-31 | 24.46% | €156.39 Million ≈ $182.83 Million |
€639.25 Million ≈ $747.36 Million |
+4.56pp |
| 2015-12-31 | 19.90% | €59.73 Million ≈ $69.83 Million |
€300.12 Million ≈ $350.87 Million |
-29.07pp |
| 2014-12-31 | 48.97% | €165.40 Million ≈ $193.37 Million |
€337.77 Million ≈ $394.89 Million |
-- |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more